Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekten av IVMED-85 på pediatrisk nærsynthet

12. november 2026 oppdatert av: iVeena Delivery Systems, Inc.

A Randomized, Vehicle-Controlled, Double-Masked Study of the Efficacy and Safety of IVMED-85 Ophthalmic Solution for the Treatment of Pediatric Myopia

To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.

The main aims are:

  • Assess the efficacy of a 12-month treatment of IVMED-85 in slowing myopia progression in pediatrics
  • Assess the safety of a 12-month treatment of IVMED-85

Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.

Studieoversikt

Detaljert beskrivelse

This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.

Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.

Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.

The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.

A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.

Studietype

Intervensjonell

Registrering (Antatt)

144

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

5 år til 10 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.

  1. Are 5 to 10 years of age
  2. Have a minimum body weight of 15.45 kg (34 lbs)
  3. Willing and able to provide informed consent and/or assent and relevant privacy authorization(s) Note: Informed consent is required from a parent/guardian and assent will be collected from subjects as appropriate for their age and maturity level. Assent may be waived for subjects under 6 years of age
  4. Willing and able to comply with clinic visits and study-related procedures
  5. Able to successfully administer ophthalmic solution or have a parent/guardian who can administer ophthalmic solution
  6. Willing and able to discontinue use of topical ocular medications for the duration of study participation Note: Artificial tears are allowed but must not be used within 30 minutes before or after administration of IP
  7. Have refractive error as determined by cycloplegic autorefraction: myopia -0.50 D to -7.0 D (spherical equivalent); astigmatism ≤3.00 D; anisometropia ≤2.00 D
  8. Have BCVA ≤0.3 logarithm of the minimum angle of resolution (logMAR) (20/40 Snellen or better)
  9. Have corneal thickness between 450 and 680 μm
  10. Have IOP ≤22 mmHg
  11. Have axial length ≥20 mm and ≤27 mm
  12. Willing to forgo swimming in an indoor pool within 1 hour before or after IP administration for the duration of study participation
  13. Willing to forgo swimming in an indoor pool within 1 hour before a clinic visit for the duration of study participation

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: IVMED-85 Low Dose

Total subjects n=48, IVMED-85 low dose BID for 12 months

Eye drop

Eksperimentell: IVMED-85 High Dose

Total subjects n=48, IVMED-85 high dose BID for 12 months

Eye drop

Placebo komparator: Placebo

Total subjects n=48, placebo BID for 12 months

Eye drop

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Refractive error change from baseline at Month 12
Tidsramme: Baseline compared to month 12

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12

Baseline compared to month 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Tidsramme: From screening to the end of treatment at 12 months

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12

From screening to the end of treatment at 12 months
Change in optical biometrics
Tidsramme: From screening to the end of treatment at 12 months

Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits

From screening to the end of treatment at 12 months
Refractive error at non-final study visits
Tidsramme: From screening to the end of treatment at 12 months

Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12

From screening to the end of treatment at 12 months
Sub foveal choroidal thickness
Tidsramme: From screening to the end of treatment at 12 months

Change from baseline in sub foveal choroidal thickness in the SE at Month 12

From screening to the end of treatment at 12 months
Accommodative amplitude in the spherical equivalent
Tidsramme: From screening to the end of treatment at 12 months

Change from baseline in accommodative amplitude in the SE at Month 12

From screening to the end of treatment at 12 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression of high myopia
Tidsramme: From screening to the end of treatment at 12 months

Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12

From screening to the end of treatment at 12 months
Progression of prospectively identified progressive myopia
Tidsramme: From screening to the end of treatment at 12 months

Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records

From screening to the end of treatment at 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Studiestol: Bala Ambati, iVeena Delivery Systems, Inc.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2027

Primær fullføring (Antatt)

1. februar 2029

Studiet fullført (Antatt)

1. juni 2029

Datoer for studieregistrering

Først innsendt

23. februar 2023

Først innsendt som oppfylte QC-kriteriene

7. mars 2023

Først lagt ut (Faktiske)

9. mars 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • IVNA 26-01

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere